Idorsia appoints Dr Mathieu Simon to its Board of Directors

– SWITZERLAND, Allschwil –  Idorsia Ltd (SWX: IDIA) today announced that at its Annual General Meeting held today in Basel, the shareholders elected all Board members who stood for re-election and elected Mathieu Simon as a new Board member for a term of office until the conclusion of the AGM 2020.

In addition, the shareholders elected Jean-Pierre Garnier as Chairperson of the Board and Jean-Pierre Garnier, John J. Greisch (Chair), Viviane Monges, and Mathieu Simon to the Nominating, Governance and Compensation Committee.

Following the AGM, the Board of Directors of Idorsia comprises a total of 6 members:

  • Jean-Pierre Garnier (Chairman),
  • Robert Bertolini,
  • Jean-Paul Clozel, CEO
  • John J. Greisch,
  • Viviane Monges,
  • Mathieu Simon.

Jean-Pierre Garnier, Chairman of the Board commented: “In 2018, Idorsia saw advances on many fronts: We advanced our pipeline, bringing four products into Phase 3 development. We completed demerger activities, with all core systems now running independently of Actelion. We appointed a leader to build our commercial organization, taking another step forward towards financial sustainability, and we strengthened our cash position so that we are able to run our Phase 3 clinical trials and then take strategic decisions on how best to commercialize our assets. These achievements represent significant progress and as a result, our shareholders have continued to give us their confidence unabatedly.”

About Idorsia

Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.